To get medicine for seriously ill Coronavirus patients, the EU Commission has bought the drug Remdesivir for NOK 671 million. Norway is also covered by the agreement.
The commission stated earlier Wednesday in a press release that the drug has been purchased from the American company Gilead. Remdesivir was approved for use in the treatment of Covid-19 in early July.
The EU has purchased medicines for around 30,000 patients who are distributed to the EU countries and the United Kingdom. The medicine is for patients who are hardest hit by the Coronavirus. It is now confirmed that Norway will also have access to the medicine.
– ‘Clinical studies have shown that Remdesivir may have an effect on the duration of treatment for patients on a ventilator. I am therefore pleased that Norway is covered by the procurement agreement we have with the EU through a so-called JPA (Joint Procurement Agreement),’ writes Minister of Health and Care Services Bent Høie (H) in an email to the newspaper.
Remdesivir is originally an Ebola medicine, but is approved for the treatment of Covid-19 in Norway and the EU.
Testing has shown that the drug can shorten the course of the disease in seriously ill Covid-19 patients from an average of eleven to fifteen days.
© NTB Scanpix / #Norway Today